FGFR2 amplification in gastric and colon cancer cell lines is associated with response to NVP-BGJ398. FGFR2 amplification in gastric and colon cancer cell.

Slides:

Advertisements

Similar presentations

Copyright © 2007 American Medical Association. All rights reserved.

Advertisements

Enhanced DNA damage in IDH1 mutant glioma cells.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

REDK, a novel human regulatory erythroid kinase

AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

IFN-γ Induces Gastric Cancer Cell Proliferation and Metastasis Through Upregulation of Integrin β3-Mediated NF-κB Signaling Yuan-Hua Xu, Zheng-Li Li,

Volume 5, Issue 3, Pages (March 2004)

Ming Hong Shen, Paulina Samsel, Louise L

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

Proline supplementation during P5CS protein knockdown suppressed GCN2 activation. Proline supplementation during P5CS protein knockdown suppressed GCN2.

Acute, systemic Atg7 deficiency compromises tumorigenesis.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

CHK1 downregulation upon ERG overexpression.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

Treatment with NVP-AEW541 shows no efficacy in an s. c

eIF5A-PEAK1 signaling regulates KRAS protein expression.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

TNFα is an important survival and growth signal for melanoma.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

Volume 19, Issue 5, Pages (May 2011)

The effects of the FASN blocker C75 on cell growth and survival (A, E, and F), on expression/phosphorylation of PI3K and MAPK signaling proteins and on.

Gramicidin A (GA) decreases HIF protein expression in RCC cells.

Epigenetic regulation of p16INK4a in human gastric cancer.

Identification of NSC as a FADD-kinase inhibitor.

The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. A, phospho-protein.

Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.

A, one-step viral growth curves: RT treatment increased the virus yield in MV-CEA–treated U87 cells by up to 2 log as compared with MV-CEA infection only.

Active AR signaling in enzalutamide-resistant xenograft tumors.

Immunohistochemistry for phosphorylated (S235) S6 ribosomal protein and quantitation of Ki67 labeling indices in vehicle- and WAY –treated Eker (Tsc2+/−)

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

IGF-IR in human head and neck cancer.

Expression pattern of TLR-4 and MyD88 in EOC cells.

RT-PCR and Western blot analysis of cIAP2 mRNA and protein expression in ovarian cancer cells. RT-PCR and Western blot analysis of cIAP2 mRNA and protein.

Dual apoptotic signaling pathways triggered by IMMU-140: Anti–HLA-DR- and SN-38–mediated signals. Dual apoptotic signaling pathways triggered by IMMU-140:

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

DNA demethylation reactivates GSN expression in gastric cancer cells.

PKCζ is tyrosine phosphorylated by EGF and contributes to EGF-induced activation of ERK in Mef cells. PKCζ is tyrosine phosphorylated by EGF and contributes.

Induction of liver NQO1 activity in juvenile female rats treated for 3 d (10 mg/kg qd SERMs or 0.1 mg/kg qd E2 or vehicle control). Induction of liver.

Changes in signal transduction pathway induced by gefitinib.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Tivantinib does not inhibit MET function.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung cancer cell lines. FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung.

Combined inhibition of coamplified RTKs is required for response.

Gene expression patterns of SLC and ABC transporters in normal and tumor tissues. Gene expression patterns of SLC and ABC transporters in normal and tumor.

Western blotting confirming the presence of fusion proteins in tumor lysates and showing increased signaling pathway activation in respective tumors. Western.

The effects of AZD1775 and olaparib on DNA damage response signaling.

BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.

LY elicits hyperphosphorylation of Akt.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.

FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.

FGF19 amplification in liver cancer cell lines is associated with response to NVP-BGJ398. FGF19 amplification in liver cancer cell lines is associated.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

Fig. 5 DDO-5936 dose-dependently impairs the growth of xenografted HCT116 cells in nude mice. DDO-5936 dose-dependently impairs the growth of xenografted.

TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3 pathway. TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3.

I3C reduces the level of Cdc25A protein in breast cancer cells.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

Presentation transcript:

FGFR2 amplification in gastric and colon cancer cell lines is associated with response to NVP-BGJ398. FGFR2 amplification in gastric and colon cancer cell lines is associated with response to NVP-BGJ398. A, box-plot showing FGFR2 copy number expressed as log2 ratio for the 541 cell lines grouped according to cancer type. B, scatter plot of gastric and large intestine cancer cell lines showing the correlation between FGFR2 DNA copy number and transcript expression. C, effect of NVP-BGJ398 on FGFR downstream signaling as measured by FRS2 Tyr-phosphorylation and Erk1/2 activation. α-Actinin and total Erk1/2 protein levels are shown as a loading control. D, SNU16 tumor xenograft–bearing nude rats received NVP-BGJ398 at the indicated doses or vehicle for 14 consecutive days (n = 6 per group). The changes over time in tumor volume are shown. Statistical analysis was conducted by 1-way ANOVA–Dunnett versus vehicle control (*, P < 0.001). E, tumor tissues were recovered 3 and 24 hours after dose treatment and analyzed for FGFR2 Tyr-phosphorylation by Western blot analysis. Total FGFR2 Western blot analysis was conducted to monitor equal loading. Pharmacodynamic analysis of tumors treated with 15 mg/kg NVP-BGJ398 was not feasible due to insufficient material. Br, breast; Ch, chondrosarcoma; Co, colorectal; En, endometrial; Es, esophagus; Ew, Ewing sarcoma; Ga, gastric; Gl, glioma; HL, hematopoietic and lymphoid tissue; HN, head and neck; Ki, kidney; Li, liver; Lu, lung; Me, melanoma; Ms, mesothelioma; Nb, neuroblastoma; Os, osteosarcoma; Ov, ovarian; Pa, pancreas; Th, thyroid; UT, urinary tract. Vito Guagnano et al. Cancer Discovery 2012;2:1118-1133 ©2012 by American Association for Cancer Research